Trial Profile
Predictors of macular oedema re-occurrence associated with branch retinal vein occlusion (BRVO) in patients treated with intravitreal bevacizumab (IVB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- 05 Aug 2016 New trial record